NovaBridge Biosciences Shares Outstanding History (NBP)
NovaBridge Biosciences reported 265.4M shares outstanding at the end of fiscal 2025.
View full NovaBridge Biosciences company overviewNovaBridge Biosciences annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 265.4M | 77.9M | +41.57% |
| 2024 | 2024-12-31 | 187.5M | 1.8M | +0.99% |
| 2023 | 2023-12-31 | 185.6M | −5.3M | −2.76% |
| 2022 | 2022-12-31 | 190.9M | 7.1M | +3.84% |
| 2021 | 2021-12-31 | 183.8M | 18.9M | +11.49% |
| 2020 | 2020-12-31 | 164.9M | 156.5M | +1871.47% |
| 2019 | 2019-12-31 | 8.4M | 0 | 0.00% |
| 2018 | 2018-12-31 | 8.4M | — | — |
NovaBridge Biosciences quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | 265.4M | 79.8M | +42.97% |
| Q3 2025 | 2025-09-30 | 265.2M | 74.3M | +38.92% |
| Q2 2025 | 2025-06-30 | 188.1M | −3.0M | −1.58% |
| Q4 2024 | 2024-12-31 | 187.5M | 3.6M | +1.97% |
| Q4 2023 | 2023-12-31 | 185.6M | 20.7M | +12.57% |
| Q4 2022 | 2022-12-31 | 190.9M | 37.3M | +24.32% |
| Q2 2022 | 2022-06-30 | 191.1M | 182.8M | +2185.20% |
| Q4 2021 | 2021-12-31 | 183.8M | 175.5M | +2097.91% |
| Q4 2020 | 2020-12-31 | 164.9M | — | — |
| Q3 2020 | 2020-09-30 | 153.5M | — | — |
| Q4 2019 | 2019-12-31 | 8.4M | — | — |
| Q4 2018 | 2018-12-31 | 8.4M | — | — |
NovaBridge Biosciences shares outstanding trends
Over the last five reported fiscal years, NovaBridge Biosciences's shares outstanding moved from 164.9M to 265.4M, a change of 100.5M. The latest reported quarter, Q4 2025, shows 265.4M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NovaBridge Biosciences filings at SEC.gov ↗